跳到正文
原文
MedTech Dive 器械媒体· Nick Paul Taylor·· 2026-10-20AI 评分40

Medtronic 获 Vitalis 心脏起搏器组合 CE 认证

Medtronic wins CE mark for Vitalis portfolio of cardiac pacemakers

AI 导读

Medtronic 获得 Vitalis 心脏起搏器组合的 CE 认证,该组合包含五款设备。其中 ReSyncra CSP、Restoria CSP 和 Refina CSP 三款具备传导系统起搏(CSP)能力,ReSyncra CSP 是功能最先进的一款。CE 认证使这些产品进入美敦力心动管理业务,该业务上一季度同比实现中个位数增长。

正文

Dive Brief:

  • Medtronic said Monday it has received a CE mark for its Vitalis portfolio of cardiac pacemakers.
  • The portfolio features five devices, which Medtronic said offer a comprehensive suite of pacing options and include features for conduction system pacing therapy, or CSP.
  • Medtronic named ReSyncra CSP as the most advanced device, highlighting its suitability for use in patients who may benefit from cardiac resynchronization therapy, or CRT, but are failed by traditional approaches to treatment.

Dive Insight:

ReSyncra is one of three pacemakers in the Vitalis portfolio with CSP capabilities. CSP is an alternative pacing technique designed to regulate heart rate and heartbeat coordination simultaneously. Medtronic described CSP as “a more physiologic pacing option for patients.”

Like ReSyncra, Restoria CSP and Refina CSP are dual-chamber pacemakers that include Medtronic’s CSP MVP pacing algorithm. Medtronic described CSP MVP as a “pacemaker programming feature designed to enhance atrioventricular synchrony through conduction system pacing sold as an integral component of cardiac pacemakers” when it filed to trademark the term last year.

AdaptivCSP is unique to ReSyncra. The feature automatically adjusts pacing timing to help optimize heart synchrony. Medtronic designed the feature for patients with heart failure in whom effective CRT cannot be achieved. While traditional CRT restores coordination by pacing both ventricles, ReSyncra uses CSP to help improve ventricular synchronization. 

Medtronic said it became the first company to receive Food and Drug Administration approval for pacing the heart’s natural conduction system in 2022, when the U.S. regulator expanded the label of a cardiac lead. The FDA approved conduction system products from Biotronik and Boston Scientific in 2024. Abbott shared first-in-human data on its Aveir CSP leadless pacemaker last year.

Medtronic’s newly CE-marked products will slot into a cardiac rhythm management unit that achieved mid-teens growth year over year in Medtronic’s most recent financial quarter. Medtronic named its Micra leadless pacing device and SelectSecure 3830 lead as drivers of the growth.

来源:MedTech Dive 器械媒体 · medtechdive.com